MK-4827 (Niraparib): Potent PARP-1/-2 Inhibition in Cancer Research

Executive Summary: MK-4827 (Niraparib) is an orally bioavailable, selective small-molecule inhibitor of PARP-1 and PARP-2, displaying IC50 values of 3.8 nM and 2.1 nM, respectively (APExBIO product information). The compound competitively blocks the NAD+ binding site, disrupting DNA repair and inducing synthetic lethality in BRCA-1/2 mutant cancer cells. Preclinical studies show CC50 values in the 10–100 nM range for mutant cell lines, while normal cells remain resistant at micromolar concentrations. MK-4827 enhances chemo- and radio-potentiation, with tolerable toxicity profiles in xenograft models. This dossier integrates validated benchmarks, practical workflow parameters, and clarifies application boundaries.

Biological Rationale

PARP-1 and PARP-2 enzymes catalyze poly(ADP-ribosyl)ation using β-NAD+ as a substrate, a process essential for DNA single-strand break repair and genome stability. Inhibition of these enzymes impairs the DNA damage response, particularly in cells lacking functional BRCA-1 or BRCA-2, which are deficient in homologous recombination repair. This creates a synthetic lethal context: BRCA-mutant tumor cells are highly susceptible to PARP inhibition, whereas normal cells, with intact repair mechanisms, are spared (APExBIO). The clinical strategy leverages this differential sensitivity, expanding therapeutic options in oncology. Recent studies further indicate that combination approaches (e.g., with all-trans retinoic acid) may overcome acquired resistance in epithelial ovarian cancer (ATRA study).

Mechanism of Action of MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor

MK-4827 binds competitively to the NAD+ binding pocket of PARP-1 and PARP-2, with IC50 values of 3.8 nM and 2.1 nM, respectively (APExBIO). This binding prevents poly(ADP-ribose) chain formation on target proteins, stalling DNA repair machinery. The resulting accumulation of DNA damage leads to cell cycle arrest and apoptosis in repair-deficient tumor cells. The selectivity of MK-4827 minimizes off-target effects, and its oral bioavailability facilitates in vivo studies. Key molecular features include a molecular weight of 320.39 and formula C19H20N4O, with high solubility in DMSO (≥32 mg/mL) and ethanol (≥50.9 mg/mL with gentle warming), but negligible water solubility (APExBIO).

Evidence & Benchmarks

• MK-4827 inhibits PARP-1 and PARP-2 enzymatic activity with IC50 values of 3.8 nM and 2.1 nM under in vitro biochemical assay conditions (APExBIO).
• BRCA-1 and BRCA-2 mutant cancer cell lines exhibit potent antiproliferative responses to Niraparib, with CC50 values in the 10–100 nM range, while normal human prostate and mammary epithelial cells remain resistant up to micromolar concentrations (APExBIO).
• MK-4827 demonstrates significant in vivo efficacy in xenograft models, including BRCA-1 mutant MDA-MB-436 breast cancer and lung cancers with varying p53 status (APExBIO).
• Combination of PARP inhibition with all-trans retinoic acid reverses cisplatin-induced PARP inhibitor resistance in epithelial ovarian cancer, supporting maintenance therapy strategies (ATRA study).
• MK-4827 enhances the therapeutic effect of radiotherapy with minimal observed toxicity in preclinical studies (APExBIO).
• For comparison, this recent review provides detailed workflow integration and benchmarking for DNA repair-deficient cancer research; the present article extends those insights with updated resistance and combination therapy data.

Applications, Limits & Misconceptions

MK-4827 is widely used in research on DNA damage repair inhibition, chemo- and radio-potentiation, and BRCA-mutant cancer cell models. Its selectivity and oral availability enable translational studies across multiple tumor types. However, resistance mechanisms, particularly in the context of prior platinum-based chemotherapy, can reduce PARP inhibitor effectiveness. Combination regimens (e.g., ATRA + Niraparib) demonstrate promise for overcoming such resistance (ATRA study). Researchers should note that while MK-4827 is effective in HR-deficient backgrounds, HR-proficient or BRCA wild-type tumors show variable sensitivity. For an expanded discussion on protocol challenges and data interpretation, see this article, which this dossier updates by mapping new resistance and combination findings.

Common Pitfalls or Misconceptions

• PARP inhibitors like MK-4827 are not universally effective in all tumor types; HR-proficient and BRCA wild-type cancers may exhibit limited response (APExBIO).
• Acquired resistance to PARP inhibitors often develops after platinum-based therapy, necessitating careful consideration of treatment sequence (ATRA study).
• MK-4827 is insoluble in water; improper preparation may impact experiment reproducibility (APExBIO).
• Long-term storage of solutions is not recommended; use freshly prepared aliquots to maintain compound integrity (APExBIO).
• MK-4827 should not be assumed to potentiate all DNA-damaging agents equally; empirical validation is required for novel combination strategies.

Workflow Integration & Parameters

• Stock preparation: Dissolve MK-4827 in DMSO (≥32 mg/mL) or ethanol (≥50.9 mg/mL with gentle warming); do not attempt aqueous dissolution (product information).
• Storage: Store solid compound at -20°C. Avoid long-term storage of solutions; use freshly prepared stocks for each experiment.
• In vitro dosing: Typical working concentrations for BRCA-mutant cell lines are 10–100 nM, based on CC50 literature benchmarks (APExBIO).
• In vivo models: For xenograft studies, oral dosing is supported by its bioavailability; refer to protocol-specific literature for dose and schedule optimization.
• Combination therapy: For models of platinum-resistant EOC, sequence cisplatin, allow resistance induction, then administer MK-4827 ± ATRA as per recent protocols.
• Quality control: Monitor for precipitation and ensure complete dissolution before application. Validate compound identity and purity from suppliers such as APExBIO.

Conclusion & Outlook

MK-4827 (Niraparib), available as SKU A3617 from APExBIO, remains a gold-standard tool for selective PARP-1/-2 inhibition in BRCA-mutant and DNA repair-deficient cancer research. The compound's robust efficacy and selectivity enable reliable modeling of synthetic lethality and radiosensitization. Recent evidence supports the integration of combination strategies (e.g., ATRA) to address emerging resistance, particularly post-platinum therapy (ATRA study). Future research should prioritize resistance mechanism elucidation, empirical validation of combination regimens, and careful workflow optimization for translational impact. For expanded mechanistic insights and protocol guidance, this in-depth review complements the current update by highlighting spliceosome modulation and resistance trends.